Global Blood Therapeutics Net Tangible Assets

Global Blood Therapeutics's net tangible assets stands at $120M as of June 2022. That compares with $320M in the prior-year period — down 62.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Global Blood Therapeutics reported $120M in net tangible assets versus $320M a year earlier — a 62.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $320M in the prior-year period — down 62.5% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Global Blood Therapeutics's net tangible assets evolved across reporting periods, while the comparison chart places GBT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Global Blood Therapeutics's reading of $120M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.